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the strain CRI41435, sharing 99% se-
quence identity. AstV-MLB1 and AstV-
MLB2 are phylogenetically related to 
the rat astroviruses RS118 and RS126. 
The remaining novel astroviruses, 
10322603 and 10621246, clustered 
closely with human, mink, and ovine 
astrovirus strain NI-295 (Figure).
This study documented that mul-
tiple novel astroviruses circulated si-
multaneously with common human as-
trovirus types in China. The detection 
rates of novel astroviruses, especially 
Ast-MLB1, were higher than in 2 pre-
vious reports (3,4), although lower 
than in a study from Egypt (9). These 
results indicate that multiple novel as-
troviruses are spread worldwide. The 
differences in prevalence may have 
been caused by the geographic and/or 
study cohort differences. The phylog-
eny of astroviruses determined in our 
study basically agrees with previous 
analyses (5), supporting the idea that 
the novel astroviruses are related to 
other animal astroviruses. Additional 
studies using full-genome sequencing 
should be done to clarify the origin of 
the novel astroviruses.
One limitation of this study was 
that no asymptomatic control was in-
cluded. A recent case–control study has 
suggested that AstV-MLB1 was not as-
sociated with diarrhea (10). However, 
other novel astroviruses were not as-
sessed. Further study, especially with 
a large case–control cohort, should be 
initiated to determine the correlation of 
unique astroviruses with gastrointesti-
nal and extraintestinal diseases.
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Call to Action for 
Dengue Vaccine 
Failure
To the Editor: Dengue is one of 
the most widespread infectious dis-
eases globally; transmission now oc-
curs in 128 countries. Although den-
gue virus (DENV) control strategies 
have targeted vector control and dis-
ease surveillance, the development of 
an effective vaccine is the holy grail 
of prevention.
Dengue vaccine development has 
spanned many decades. A candidate 
vaccine (Sanofi Pasteur, Swiftwater, 
PA, USA) containing all 4 DENV se-
rotypes is in advanced clinical testing. 
However, when given to school chil-
dren in Thailand, this live-attenuated, 
tetravalent, dengue–yellow fever 17D 
chimeric virus vaccine showed ma-
jor but incomplete efficacy against 
3 of the 4 DENV serotypes (DENV 
1 [61.2%], DENV-3 [81.3%], and 
DENV-4 [89.9%]) in the intention-to-
treat group but no protection against 
DENV 2, the most pathogenic of the 
DENV serotypes (1).
Two observations from the effi-
cacy trial in Thailand provide insights 
into protective immunity that could 
greatly improve second-generation 
vaccines. The first observation was 
that a single dose of 4 live-attenuated 
chimeric DENVs given subcutane-
ously at a single site failed to raise 
type-specific protective immunity 
against the 4 DENV serotypes, and 
2) doses 2 and 3 of the Sanofi Pas-
teur vaccine given to children over 
a 1-year period failed to improve ef-
ficacy outcomes. These results were 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	19,	No.	8,	August	2013	 1335
1These	 authors	 contributed	 equally	 to	 this	
article.
LETTERS
obtained even though 91% of the chil-
dren had circulating dengue or Japa-
nese encephalitis antibodies before 
vaccination, neutralizing antibodies 
developed to all 4 DENVs, and neu-
tralizing antibody titers increased 2–3 
fold after 3 doses of vaccine in 80%–
90% of vaccinated children.
The inability of a mixture of 4 
dengue chimeric viruses to elicit an 
initial primary neutralizing antibody 
response in nonhuman primates and 
susceptible humans was recognized 
during preclinical testing and ex-
plained by the phenomenon of in-
terference (2). Although protective 
immunity was raised in susceptible 
rhesus monkeys inoculated with all 
4 DENVs at a single site, inoculation 
of 4 chimeric dengue viruses at 1 or 2 
sites did not result in neutralizing an-
tibody responses to all 4 DENV (3). 
Studies on human primary immune 
responses to dengue infection have 
identified critical attachment sites on 
the virion for neutralizing antibod-
ies (4). Serum samples from children 
given ≥1 doses of the dengue chime-
ric vaccine can now be tested for pri-
mary neutralizing antibody responses 
to each of the 4 DENVs. As an al-
ternative, antibody-secreting cells 
may be isolated and their products 
identified by using methods as de-
scribed for dengue-infected children 
in Nicaragua (5).
Infections with 2 different DEN-
Vs can protect against severe disease 
during subsequent infections (6). It 
has therefore been assumed that per-
sons with DENV neutralizing antibod-
ies are protected against infection. In 
clinical testing of the Sanofi Pasteur 
vaccine, failure of multiple booster 
doses to show protection was un-
expected because the children were 
already substantially immune from 
prior exposure to DENV or Japanese 
encephalitis vaccine. When the tetra-
valent dengue chimeric vaccine was 
given to partially dengue–immune 
children and adults in the Philippines, 
a broad neutralizing antibody response 
was observed after administration of 
only 2 vaccine doses (7).
We believe that the unanticipated 
results of the dengue vaccine efficacy 
trial in Thailand call for new methods 
of assessing dengue immunity. My-
eloid cells are major targets of dengue 
infection in humans. We and others 
have described the unique biologic re-
sponses when dengue virus–antibody 
complexes are presented to myeloid 
cells (8). There is evidence that DENV 
neutralization titers differ when the 
same antibodies are assayed in epithe-
lial and Fc-receptor–bearing cells (8). 
Recent work suggests that primary 
monocytes and macrophages may not 
respond in exactly the same fashion 
to infection by DENV immune com-
plexes (8). Few relevant studies exist 
in the literature, and most focused on 
DENV-2. Detailed studies on innate 
immune responses in human myeloid 
cells with a variety of dengue immune 
complexes should proceed forthwith.
To our knowledge, only once has 
an in vitro test correctly predicted 
which children would be susceptible 
or have silent infections accompany-
ing a second heterotypic dengue in-
fection (9). This was determined by 
using serum samples collected before 
a second dengue infection and testing 
these serum samples at low dilutions 
for their ability to protect primary hu-
man monocytes from DENV-2 infec-
tion or antibody-dependent enhanced 
infection. During development of the 
Sanofi Pasteur tetravalent chimeric 
dengue vaccine, serum samples from 
vaccinated persons were routinely 
tested for neutralization of DENV in 
an epithelial cell line (10). In addition 
to assaying for antibodies directed at 
the quaternary site described by de Al-
wis et al. (4), we suggest that serum 
samples from vaccinated persons be 
tested for neutralization of all DENVs 
in primary human myeloid cells.
Although human Fc-receptor cell 
lines may be convenient for assaying 
DENV antibodies, decisions regarding 
their use should be deferred until they 
are shown to model primary myeloid 
cells. Because antibody titers often 
wane after vaccination, the ability of 
serum samples from vaccinees to pro-
tect against infection of myeloid cells 
with the 4 DENVs should be studied 
over many years. Changes to in vitro 
systems for measuring immune re-
sponses after dengue vaccination may 
provide a better surrogate of protec-
tion by realigning antibody measure-
ment systems to our contemporary 
understanding of the pathogenesis of 
this complex disease.
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Novel Norovirus 
 GII.4 Variant, 
Shanghai, China, 
2012
To the Editor: Norovirus (NoV) 
has been identified as one of the major 
causal agents of nonbacterial, acute 
gastroenteritis in humans (1). The ge-
netic diversity among NoVs is great, 
and human strains have been classified 
into 3 genogroups (GI, GII, and GIV). 
Despite this diversity, in recent years 
only a few strains, primarily those 
of genogroup II, genotype 4 (GII.4), 
have been responsible for most cases 
and outbreaks worldwide (1,2).
The pattern of epochal evolution 
of NoV is ongoing, and novel GII.4 
variants emerge, which replace pre-
viously dominant strains and cause 
new pandemics. Surveillance systems 
worldwide showed an increase in NoV 
activity in late 2012 (3). Molecular 
data shared through NoroNet (www.
rivm.nl/en/Topics/Topics/N/NoroNet) 
suggest that this increase is related to 
the emergence of a new GII.4 vari-
ant, termed Sydney_2012 (3). We 
found that this novel GII.4 variant 
also emerged in Shanghai, China, and 
caused increased levels of NoV activ-
ity during October–December 2012.
During July 2011–December 
2012, fecal specimens from 748 out-
patients (>16 years of age) with acute 
gastroenteritis who visited 1 of the 2 
sentinel hospitals in Shanghai were 
collected and stored at Shanghai Pub-
lic Health Clinical Center at −70°C. 
Molecular detection of GI and GII 
NoV was performed by using con-
ventional reverse transcription PCR 
as described (4). Full-length viral 
protein 1 and 639 bp of the 3′ RNA-
dependent RNA polymerase gene of 4 
randomly selected GII-positive strains 
were amplified (5–7). NoV genotypes 
were classified on the basis of a 280-
bp region for GI and a 305-bp region 
for GII by using the Automated Ge-
notyping Tool (www.rivm.nl/mpf/ 
norovirus/typingtool).
A total of 77 patients showed 
positive results for GII NoV. An in-
crease in GII NoV activity was ob-
served during October–December in 
2012; the detection rate was 46.08% 
(47 cases in 102 outpatients). The 
prevalence of GII NoV during the 
same period in 2011 was low; the de-
tection rate was 6.90% (8 cases in 116 
outpatients). Genotyping analysis of 
the strains detected in these 3 months 
in 2012 (39 strains were sequenced) 
showed that except for 1 GII.6 strain 
and 3 GII.4 2006b strains, the other 
35 strains sequenced all belong to 
the new established cluster of GII.4, 
termed Sydney_2012. Retrospective 
analysis indicated that the novel GII.4 
variant had already been detected in 2 
outpatients during September 2011 in 
Shanghai.
Phylogenetic analysis of full-
length capsid nucleotide sequences 
for 4 strains randomly selected from 
the new cluster indicated a novel 
GII.4 pattern, and new strains clus-
tering separately from previously 
identified GII.4 pandemic strains 
(Figure). On the basis of BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.
cgi) searches, the most closely re-
lated NoVs (98%–100% nucleotide 
identity) were 4 GII.4 viruses re-
cently detected in Australia and Hong 
Kong. The new GII.4 strains detected 
in Shanghai also clustered with these 
strains, a finding that was supported 
by bootstrap values >70% (Figure). 
The 3′ end of RNA-dependent RNA 
polymerase gene sequences also 
confirmed that the new GII.4 strains 
were recombinants, with a GII.e poly-
merase and GII.4 capsid (3).
Despite improved control mea-
sures to combat NOV, this highly infec-
tious agent continues to cause a large 
number of epidemics of gastroenteritis 
globally (approximately every 2 years), 
and most epidemics have been associ-
ated with emergence of a novel GII.4 
cluster (9). The new cluster reported 
in the present study was first detected 
in Australia in March, 2012, followed 
by detection in France, New Zealand, 
Japan, the United Kingdom, the Unit-
ed States, and Hong Kong, where in-
creased levels of NoV activity in late 
2012 compared with previous seasons 
were also observed (3). This novel 
GII.4 strain has also emerged in Shang-
hai, China, and caused increased levels 
of sporadic cases during October–and 
December 2012. This new variant has 
common ancestors, dominant NoV 
GII.4 variants Osaka_2007 and New 
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